Protective effect of UDCA against IL-11- induced cardiac fibrosis is mediated by TGR5 signalling.

Autor:	Reilly-O'Donnell B; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Ferraro E; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Tikhomirov R; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Nunez-Toldra R; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Shchendrygina A; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Patel L; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Wu Y; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Mitchell AL; Department of Women and Children's Health, King's College London, London, United Kingdom., Endo A; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Adorini L; Intercept Pharmaceuticals Inc., New York, NY, United States., Chowdhury RA; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Srivastava PK; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Ng FS; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Terracciano C; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Williamson C; Department of Women and Children's Health, King's College London, London, United Kingdom., Gorelik J; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Jazyk:	angličtina
Zdroj:	Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2024 Dec 03; Vol. 11, pp. 1430772. Date of Electronic Publication: 2024 Dec 03 (Print Publication: 2024).
DOI:	10.3389/fcvm.2024.1430772
Abstrakt:	Introduction: Cardiac fibrosis occurs in a wide range of cardiac diseases and is characterised by the transdifferentiation of cardiac fibroblasts into myofibroblasts these cells produce large quantities of extracellular matrix, resulting in myocardial scar. The profibrotic process is multi-factorial, meaning identification of effective treatments has been limited. The antifibrotic effect of the bile acid ursodeoxycholic acid (UDCA) is established in cases of liver fibrosis however its mechanism and role in cardiac fibrosis is less well understood. Methods: In this study, we used cellular models of cardiac fibrosis and living myocardial slices to characterise the macroscopic and cellular responses of the myocardium to UDCA treatment. We complemented this approach by conducting RNA-seq on cardiac fibroblasts isolated from dilated cardiomyopathy patients. This allowed us to gain insights into the mechanism of action and explore whether the IL-11 and TGFβ/WWP2 profibrotic networks are influenced by UDCA. Finally, we used fibroblasts from a TGR5 KO mouse to confirm the mechanism of action. Results and Discussion: We found that UDCA reduced myofibroblast markers in rat and human fibroblasts and in living myocardial slices, indicating its antifibrotic action. Furthermore, we demonstrated that the treatment of UDCA successfully reversed the profibrotic IL-11 and TGFβ/WWP2 gene networks. We also show that TGR5 is the most highly expressed UDCA receptor in cardiac fibroblasts. Utilising cells isolated from a TGR5 knock-out mouse, we identified that the antifibrotic effect of UDCA is attenuated in the KO fibroblasts. This study combines cellular studies with RNA-seq and state-of-the-art living myocardial slices to offer new perspectives on cardiac fibrosis. Our data confirm that TGR5 agonists, such as UDCA, offer a unique pathway of action for the treatment of cardiac fibrosis. Medicines for cardiac fibrosis have been slow to clinic and have the potential to be used in the treatment of multiple cardiac diseases. UDCA is well tolerated in the treatment of other diseases, indicating it is an excellent candidate for further in-human trials. Competing Interests: LA is a consultant for Intercept Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (© 2024 Reilly-O'Donnell, Ferraro, Tikhomirov, Nunez-Toldra, Shchendrygina, Patel, Wu, Mitchell, Endo, Adorini, Chowdhury, Srivastava, Ng, Terracciano, Williamson and Gorelik.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu